Policy paper

Cannabis-based products for medicinal use in humans: commission to the ACMD

The Home Secretary has formally commissioned the Advisory Council on the Misuse of Drugs (ACMD) to conduct a longer-term review of cannabis-based products for medicinal use.

• From: Home Office
• Published: 15 February 2019

Documents

Cannabis-based products for medicinal use in humans: commission to the ACMD (accessible version)

HTML

Cannabis-based products for medicinal use in humans: commission to the ACMD

PDF, 320 KB, 6 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email alternativeformats@homeoffice.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

The ACMD issued their short-term advice on 19 July and 11 September with a set of recommendations for both the Home Office and the Department of Health and Social Care (DHSC). On 1 November, cannabis-based products for medicinal use were added to Schedule 2 under the 2001 Regulations.

Published 15 February 2019